Industry

Interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the start of treatment. AMSTERDAM–(BUSINESS WIRE)–Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the … [Read more…]

Results showed improved or preserved cognitive function in a majority of people regardless of baseline values, with the greatest effect observed in almost 80% of people with high thalamic volume (45.5% improved and 34.1% preserved) at Month 48 of the DAYBREAK open-label extension trial Zeposia was well tolerated, with more than 80% of people staying … [Read more…]

Analysis of ongoing DAYBREAK open-label extension trial of Zeposia showed that seroconversion occurred in 100% of those treated with mRNA vaccines and in a majority of those treated with non-mRNA vaccines New analyses to be featured in late-breaking research session at the 8th European Academy of Neurology Congress in Vienna, Austria Data are among five … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Lutetium-177 (Lu-177) Global Market and Pipeline Analysis – Forecast to 2028” report has been added to ResearchAndMarkets.com’s offering. Lutetium-177 (Lu-177) Global Market and Pipeline Analysis – Forecast to 2028″ gives comprehensive insights on the various Lu-177 based drugs being developed for the treatment of prostate cancer, NETs, Lung cancer, solid tumors and other … [Read more…]

— Data being presented at the European Academy of Neurology Congress demonstrates consistent reductions in NMOSD attacks and disability scores across populations — DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) today announced new findings from a post hoc analysis of the N-MOmentum Phase 3 pivotal trial of UPLIZNA supporting the medicine’s efficacy in Europeans living with … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Specialty Drug Distribution Market Research Report by Indication (AIDS, Hemophilia, and Multiple Sclerosis), Type, Distribution Type, Distribution Channel, State – United States Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The United States Specialty Drug Distribution Market size was estimated at USD 340.41 million in 2021 … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Body Contouring Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering. The global body contouring market reached a value of $7.3 Billion in 2021. Looking forward, the publisher expects the market to reach $11.1 Billion by 2027, exhibiting a CAGR of 6.9% during 2022-2027. … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Urethral Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players” report has been added to ResearchAndMarkets.com’s offering. Scope The pipeline guide provides a snapshot of the global therapeutic landscape of Urethral Cancer The pipeline guide reviews pipeline therapeutics for Urethral Cancer by companies and universities/research institutes based on … [Read more…]

SEATTLE–(BUSINESS WIRE)–Kubota Vision Inc. (“Kubota Vision”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the completion of the phase 3 clinical trial investigating emixustat hydrochloride (“emixustat”) in patients with macular atrophy secondary to Stargardt disease. The study was a multi-center, randomized, double-masked, and placebo-controlled phase 3 … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Geographic Atrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players” report has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive information on the therapeutics under development for Geographic Atrophy, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and … [Read more…]